Dual function of tributyrin emulsion: Solubilization and enhancement of anticancer effect of celecoxib

International Journal of Pharmaceutics

Volumn 428, Issue 1-2, 2012, Pages 76-81

  Kang, Sung Nam ^a   Hong, Soon Seok ^a   Lee, Mi Kyung ^b   Lim, Soo Jeong ^a  

^a Sejong University   (South Korea)

^b Woosuk University   (South Korea)

Author keywords

Cancer; Celecoxib; Emulsion; Formulation; Tributyrin

Indexed keywords

CELECOXIB; TRIBUTYRIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; DRUG EFFICACY; DRUG POTENTIATION; DRUG SOLUBILITY; EMULSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG CARRIERS; DRUG SYNERGISM; EMULSIONS; HCT116 CELLS; HUMANS; MELANOMA; MICE; OILS; PARTICLE SIZE; PRODRUGS; PYRAZOLES; SOLUBILITY; SULFONAMIDES; SURFACE-ACTIVE AGENTS; TRIGLYCERIDES;

EID: 84862811750     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.02.037     Document Type: Article

References (28)

1. L.H. Augenlicht, J.M. Mariadason, A. Wilson, D. Arango, W. Yang, B.G. Heerdt, and A. Velcich Short chain fatty acids and colon cancer J. Nutr. 132 2002 3804S 3808S (Pubitemid 35435069)
2. W.M. Awara, A.E. El-Sisi, M.E. El-Sayad, and A.E. Goda The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacol. Res. 50 2004 487 498 (Pubitemid 39349050)
3. S. Baboota, F. Shakeel, A. Ahuja, J. Ali, and S. Shafiq Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib Acta Pharm. 57 2007 315 332 (Pubitemid 47429175)
4. F. Buyukozturk, J.C. Benneyan, and R.L. Carrier Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics J. Control Release. 142 2010 22 30
5. H. Choy, and L. Milas Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance J. Natl. Cancer Inst. 95 2003 1440 1452 (Pubitemid 37279329)
6. K.O. Clarke, R. Feinman, and L.E. Harrison Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3 Cancer Lett. 171 2001 57 65 (Pubitemid 32727356)
7. D.F. Driscoll Lipid injectable emulsions: pharmacopeial and safety issues Pharm. Res. 23 2006 1959 1969
8. R. Hakem, J.L. de la Pompa, A. Elia, J. Potter, and T.W. Mak Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation Nat. Genet. 16 1997 298 302 (Pubitemid 27280216)
9. B.G. Heerdt, M.A. Houston, G.M. Anthony, and L.H. Augenlicht Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity Cancer Res. 59 1999 1584 1591 (Pubitemid 29160130)
10. D.I. Kang, S. Lee, J.T. Lee, B.J. Sung, J.Y. Yoon, J.K. Kim, J. Chung, and S.J. Lim Preparation and in vitro evaluation of anti-VCAM-1-Fab'-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib J. Microencapsul. 28 2011 220 227
11. H.K. Kang, E. Lee, H. Pyo, and S.J. Lim Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells Mol. Cancer Ther. 4 2005 1358 1363
12. S.N. Kang, E. Lee, M.K. Lee, and S.J. Lim Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma Drug Deliv. 18 2011 143 149
13. C.H. Koehne, and R.N. Dubois COX-2 inhibition and colorectal cancer Semin. Oncol. 31 2004 12 21 (Pubitemid 38879410)
14. A. Kuwajima, J. Iwashita, J. Murata, and T. Abe The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of matrigel Anticancer Res. 27 2007 4163 4169
15. Y. Li, S. Le Maux, H. Xiao, and D.J. McClements Emulsion-based delivery systems for tributyrin, a potential colon cancer preventative agent J. Agric. Food Chem. 57 2009 9243 9249
16. K. Margulis-Goshen, E. Kesselman, D. Danino, and S. Magdassi Formation of celecoxib nanoparticles from volatile microemulsions Int. J. Pharm. 393 2010 230 237
17. P.A. Marks, V.M. Richon, and R.A. Rifkind Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J. Natl. Cancer Inst. 92 2000 1210 1216 (Pubitemid 30627729)
18. A. Munshi, J.F. Kurland, T. Nishikawa, T. Tanaka, M.L. Hobbs, S.L. Tucker, S. Ismail, C. Stevens, and R.E. Meyn Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity Clin. Cancer Res. 11 2005 4912 4922 (Pubitemid 41557212)
19. C. Schroder, K. Eckert, and H.R. Maurer Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro Int. J. Oncol. 13 1998 1335 1340
20. N. Seedher, and S. Bhatia Solubility enhancement of Cox-2 inhibitors using various solvent systems AAPS PharmSciTech 4 2003 E33
21. F. Shakeel, S. Baboota, A. Ahuja, J. Ali, and S. Shafiq Celecoxib nanoemulsion: skin permeation mechanism and bioavailability assessment J. Drug Target 16 2008 733 740
22. R.G. Strickley Solubilizing excipients in oral and injectable formulations Pharm. Res. 21 2004 201 230 (Pubitemid 38221966)
23. J. Su, and P.C. Ho Preparation of tributyrin emulsion and characterization of the binding of the emulsion particles to low-density lipoprotein in vitro J. Pharm. Sci. 93 2004 1755 1765 (Pubitemid 38823703)
24. N. Subramanian, S. Ray, S.K. Ghosal, R. Bhadra, and S.P. Moulik Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib Biol. Pharm. Bull. 27 2004 1993 1999 (Pubitemid 41701577)
25. R.T. Utley, K. Ikeda, P.A. Grant, J. Cote, D.J. Steger, A. Eberharter, S. John, and J.L. Workman Transcriptional activators direct histone acetyltransferase complexes to nucleosomes Nature 394 1998 498 502 (Pubitemid 28373963)
26. P. Venkatesan, N. Puvvada, R. Dash, B.N. Prashanth Kumar, D. Sarkar, B. Azab, A. Pathak, S.C. Kundu, P.B. Fisher, and M. Mandal The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer Biomaterials 32 2011 3794 3806
27. E. Weisberg, L. Catley, J. Kujawa, P. Atadja, S. Remiszewski, P. Fuerst, C. Cavazza, K. Anderson, and J.D. Griffin Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo Leukemia 18 2004 1951 1963 (Pubitemid 40028421)
28. K. Zielinska, K.A. Wilk, A. Jezierski, and T. Jesionowski Microstructure and structural transition in microemulsions stabilized by aldonamide-type surfactants J. Colloid Interface Sci. 321 2008 408 417